Literature DB >> 22898992

Sildenafil vs. sodium before nitroprusside for the pulmonary hypertension reversibility test before cardiac transplantation.

Aguinaldo Figueiredo Freitas1, Fernando Bacal, José de Lima Oliveira Júnior, Alfredo Inácio Fiorelli, Ronaldo Honorato Santos, Luiz Felipe Pinho Moreira, Christiano Pereira Silva, Sandrigo Mangini, Jeane Mike Tsutsui, Edimar Alcides Bocchi.   

Abstract

BACKGROUND: Pulmonary hypertension is associated with a worse prognosis after cardiac transplantation. The pulmonary hypertension reversibility test with sodium nitroprusside (SNP) is associated with a high rate of systemic arterial hypotension, ventricular dysfunction of the transplanted graft and high rates of disqualification from transplantation.
OBJECTIVE: This study was aimed at comparing the effects of sildenafil (SIL) and SNP on hemodynamic, neurohormonal and echocardiographic variables during the pulmonary reversibility test.
METHODS: The patients underwent simultaneously right cardiac catheterization, echocardiography, BNP measurement, and venous blood gas analysis before and after receiving either SNP (1 - 2 µg/kg/min) or SIL (100 mg, single dose).
RESULTS: Both drugs reduced pulmonary hypertension, but SNP caused a significant systemic hypotension (mean blood pressure - MBP: 85.2 vs. 69.8 mm Hg; p < 0.001). Both drugs reduced cardiac dimensions and improved left cardiac function (SNP: 23.5 vs. 24.8%, p = 0.02; SIL: 23.8 vs. 26%, p < 0.001) and right cardiac function (SIL: 6.57 ± 2.08 vs. 8.11 ± 1.81 cm/s, p = 0.002; SNP: 6.64 ± 1.51 vs. 7.72 ± 1.44 cm/s, p = 0.003), measured through left ventricular ejection fraction and tissue Doppler, respectively. Sildenafil, contrary to SNP, improved venous oxygen saturation, measured on venous blood gas analysis.
CONCLUSION: Sildenafil and SNP are vasodilators that significantly reduce pulmonary hypertension and cardiac geometry, in addition to improving biventricular function. Sodium nitroprusside, contrary to SIL, was associated with systemic arterial hypotension and worsening of venous oxygen saturation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22898992     DOI: 10.1590/s0066-782x2012005000076

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  1 in total

1.  Sildenafil for noncompaction cardiomyopathy treatment in a child: case report.

Authors:  Ana Carolina Costa Redondo; Gabriela Fuenmayor; Karen Saori Shiraishi; Simone Rolim F Fontes; Patrícia Figueiredo Elias; Rogerio Souza; Ieda Biscegli Jatene
Journal:  Arq Bras Cardiol       Date:  2014-03       Impact factor: 2.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.